Tamoxifen for early breast cancer: an overview of the randomised trials

@article{Abe1998TamoxifenFE,
  title={Tamoxifen for early breast cancer: an overview of the randomised trials},
  author={O. Abe and R. Abe and K. Enomoto and K. Kikuchi and H. Koyama and Y. Nomura and K. Sakai and K. Sugimachi and T. Tominaga and J. Uchino and M Yoshida and AO van de Velde and J. V. Dongen and J. Vermorken and G. Giokas and B. Lissaios and V. Harvey and TM Holdaway and R. Kay and BH Mason and A. Coates and J. Forbes and C. Focan and J. Lobelle and U. Peek and G. Oates and J. Powell and M. Durand and L. Mauriac and S. Bartholomeus and M. Piccart and R. Gelman and Jay R. Harris and Claire Shapiro and A. Hancock and M. Masood and D. Parker and J. Price and S. Jackson and J. Ragaz and T. Delozier and J. Mac{\'e}-Lesec’h and J. Haybittle and C. Cirrincione and I. Henderson and A. Korzun and R. Weiss and W. Wood and M. Baum and J. Houghton and D. Riley and D. Dent and C. Gudgeon and A. Hacking and K. Horgan and L. Hughes and H. Stewart and NH Gordon and HL Davis and P. Romestaing and Y. Lehingue and J. Owen and P. Meier and A. Howell and G. Ribeiro and R. Swindell and J. Albano and Cf Oliveira and H. Gerv{\'a}sio and J. Gordilho and B. Carstensen and T. Palshof and H. Johansen and S. Korzeniowski and J. Skołyszewski and S. Portnoj and K. Andersen and C. Axelsson and M. Blichert-toft and H. Mouridsen and M. Overgaard and C. Rose and N. Corcoran and HJ Trampisch and RL Comis and N. Davidson and R. Gray and N. Robert and D. Tormey and J. Rossbach and L. Bijnens and C. V. D. Velde and M. Cunningham and G. Bastert and H. Rauschecker and R. Sauer and W. Sauerbrei and A. Schauer and M. Schumacher and A. D. Schryver and M. Belfiglio and E. Mari and A. Nicolucci and N. Scorpiglione and H. Yosef and C. McArdle and DC Smith and P. Lara and F. Boccardo and A. Rubagotti and A. Erazo and JY Medina and M. Izuo and Y. Morishita and A. Bentley and Z. Doran and I. Fentiman and J. Hayward and R. Rubens and M. Kaufmann and W. Jonat and D. Fournier and G. Fountzilas and P. Klefstrom and C. Blomqvist and J. Cuzick and R. Margreiter and M. Castiglione and F. Cavalli and J. Collins and R. Gelber and A. Goldhirsch and J. Lindtner and K. Price and C. Rudenstam and H. Senn and J. Bliss and R. C. Coombes and M. Marty and R. Borovik and G. Brufman and H. Hayat and Elise B. Robinson and N. Wigler and F. Pannuti and S. Takashima and T. Yasutomi and H. Sonoo and J. Yamashita and M. Ogawa and P. Hupperets and J. Bonte and I. Tengrup and L. Tennvall-Nittby and P. Martin and S. Romain and D. Ahmann and D. Schaid and A. Buzdar and Terry L. Smith and T. Hakes and L. Norton and R. Wittes and R. D. Huerta and MG Sainz and G. Bonadonna and M. D. Vecchio and P. Valagussa and U. Veronesi and JB Dubois and A. Bianco and M. Lippman and L. Pierce and R. Simon and S. Steinberg and J. Myles and J. Pater and K. Pritchard and S. Anderson and A. Brown and J. Bryant and J. Costantino and J. Dignam and B. Fisher and C. Redmond and S. Wieand and N. Wolmark and I. Jackson and M. Palmer and J. Ingle and V. Suman and N. Bengtsson and L. Larsson and J. Lythgoe and M. Kissin and E. Hannisdal and JE Varhaug and R. Nissen-Meyer and R. Blamey and A. Mitchell and J. Robertson and Y. Nakamura and G. M{\'a}th{\'e} and J. Misset and H. Abu-Zahra and E. Clarke and J. McLaughlin and R. Clark and M. Levine and K. Morimoto and K. Sawa and Y. Takatsuka and S. Gundersen and M. Hauer-Jensen and H. H{\o}st and E. Crossley and A. Harris and C. Baker and A. Beighton and M. Clarke and R. Collins and C. Davies and T. Elphinstone and V. Evans and J. Godwin and E. Greaves and C. Harwood and A. Headon and C. Hicks and D. Jackson and Spencer L. James and E. Lau and P. Mcgale and G. C. Mead and H. Monaghan and S. Mozley and A. Naughten and R. Peto and A. Tooth and K. Wheatley and P. Rambert and B. Asselain and R. Salmon and J. Vilcoq and R. Arriagada and C. Hill and A. Laplanche and M. L{\^e} and M. Spielmann and G. Cocconi and B. Blasio and R. Catalano and R. Creech and J. Brockschmidt and M. R. Cooper and O. Andrysek and J. Barkmanova and C. Falkson and M. Abraham and J. Klijn and A. Treurniet‐Donker and W. V. Putten and D. Easton and T. Powles and J. Gazet and V. Semiglazov and A. Businico and S. Sardinia and N. Deshpande and L. D. Martino and P. Douglas and A. Lindtner and G. Notter and A. J. Bryant and G. H. Ewing and J. L. Krushen-Kosloski and A. Forrest and W. Jack and C. McDonald and T. M{\"o}ller and S. Ryd{\'e}n and J. Carstensen and T. Hatschek and M. S{\"o}derberg and J. Carpenter and K. Albain and J. Crowley and S. Green and S. Martino and C. Osborne and P. Ravdin and L. Rutqvist and A. Wallgren and L. Holm and B. Th{\"u}rlimann and H. Brenner and A. Hercbergs and M. Yoshimoto and G. Deboer and A. Paterson and J. Meakin and T. Panzarella and A. Naja and J. Bahi and M. Reid and M. Spittle and F. Senanayake and R. Love and D. L. D. Mets and J. Bergh and L. Holmberg and P. Sevelda and C. Zielinsky and M. Gnant and R. Jakesz and R. Buchanan and G. Royle and J. Dunn and W. Gillespie and K. Kelly and J. M. Morrison and A. Litton and R. Chlebowski and W. Bezwoda and H. Caffier},
  journal={The Lancet},
  year={1998},
  volume={351},
  pages={1451-1467}
}
BACKGROUND There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented. METHODS In 1995, information was sought on each woman in any randomised trial that began before 1990 of adjuvant tamoxifen versus no tamoxifen before recurrence. Information was obtained and analysed centrally on each of 37000 women in 55 such trials, comprising about 87% of the worldwide evidence. Compared with the previous such… Expand
Tamoxifen in early breast cancer
TLDR
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and the proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reduction were greater in node- positive women. Expand
WITHDRAWN: Tamoxifen for early breast cancer.
  • M. Clarke
  • Medicine
  • The Cochrane database of systematic reviews
  • 2008
TLDR
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and the proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reduction were greater in node- positive women. Expand
EDITORIALS Tamoxifen and Contralateral Breast Cancer: the Other Side
TLDR
In this issue of the Journal, Li et al. report that they did not find a statistically significant reduction in contralateral breast cancer in women treated with adjuvant tamoxifen, with a hazard ratio of 0.9 (95% confidence interval [CI] 0.7 to 1.2). Expand
Tamoxifen – An Update on Current Data and Where it Can Now be Used
  • L. Wickerham
  • Medicine
  • Breast Cancer Research and Treatment
  • 2004
Over the past 30 years, data from a large number of clinical trials have confirmed the efficacy of tamoxifen in estrogen receptor (ER)-positive breast cancer, both as adjuvant therapy and forExpand
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
TLDR
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo. Expand
Adjuvant Therapy for Breast Cancer: A Summary of the Early Breast Cancer Trialists’ Collaborative Group (Oxford) Overview
TLDR
The role of adjuvant ovarian ablation, Tamoxifen and chemotherapy in women treated for breast cancer surgically with curative intent has clarified and reduced recurrence and mortality in estrogen receptor-positive women of any age or nodal status. Expand
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
  • K. Pritchard
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
The trial by Boccardo et al, which is published in this issue of the Journal of Clinical Oncology, represents the fourth published randomized trial of an adjuvant aromatase inhibitor used either instead of or after 2 to 3 or 5 years of tamoxifen, and should allow clinicians and patients to make a relatively informed choice regarding the desirability of this treatment. Expand
Overview of the main outcomes in breast-cancer prevention trials
TLDR
Although tamoxifen cannot yet be recommended as a preventive agent (except possibly in women at very high risk with a low risk of side-effects), continued follow-up of the current trials is essential for identification of a subgroup of high-risk, healthy women for whom the risk-benefit ratio is sufficiently positive. Expand
Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer
  • J. Ingle
  • Medicine
  • Clinical Cancer Research
  • 2006
TLDR
The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastroZole over continuing the tamoxIFen to complete the full 5 years of adjuvant therapy. Expand
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
TLDR
Based on the results of these studies, the use of an aromatase inhibitor for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer has largely replaced the previous standard of 5 years of tamoxifen. Expand
...
1
2
3
4
5
...